Founder & Members
Ozgur Sahin, PhD
Dr. Sahin is an experienced cancer biologist with a strong background in cancer biology, functional genomics, bioinformatics, and drug discovery. He discovered the roles of many proteins and non-coding RNAs in the pathogenesis of drug resistant and metastatic cancers. Dr. Sahin is currently a Professor and Endowed Chair in the Department of Biochemistry & Molecular Biology and the Co-leader of the Breast Transdisciplinary Cancer Team (TcT) at Hollings Cancer Center at Medical University of South Carolina (MUSC), Charleston, SC. Previously, he served as Research Team Leader at German Cancer Research Center (DKFZ), Research Faculty in the Department of Molecular & Cellular Oncology at the University of Texas MD Anderson Cancer Center (MDACC), Assistant Professor in the Department of Molecular Biology & Genetics at Bilkent University and Associate Professor in the Department of Drug Discovery & Biomedical Sciences at the University of South Carolina. To date, Dr. Sahin published more than 70 peer-reviewed papers in the field of cancer research in high impact international journals and filed multiple patent applications. He is also co-founder and manager of OncoCube Therapeutics and a member of the scientific advisory board of A2A Pharmaceuticals.
Email: sahin@loxigen.com
Founder and President
HM Lee, PhD
HM Lee is a faculty at the Department of Biochemistry and Molecular Biology and Hollings Cancer Center at the Medical University of South Carolina. He is actively contributing to the development of LOX inhibitors with a rich interdisciplinary background of oncology, pharmacology, and cell biology. He has published several major breakthroughs (full list: https://tinyurl.com/4bacr2u7). As a core R&D personnel, his research focus is to develop novel class of LOX inhibitors with excellent drug-like properties.
Email: hmlee@loxigen.com
Director of Research